Repare Therapeutics Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company focused on synthetic lethality. Founded in 2016 by top academics, the company employs its proprietary SNIPRx® platform to discover and develop targeted cancer therapies, especially those related to genomic instability and DNA damage repair. Its mission is to be a top biopharmaceutical company in developing precision oncology small molecule therapies based on synthetic lethality, aiming to help patients with high unmet medical needs through innovative therapies and a strong scientific approach.
Industries
Nr. of Employees
medium (51-250)
Repare Therapeutics Inc.
Products
Pangenomic CRISPR discovery platform
A discovery platform that combines genome-scale CRISPR screening with isogenic cell-line panels and large-scale tumor genomic analysis to nominate synthetic-lethality targets and patient-selection biomarkers.
Polθ ATPase inhibitor (clinical program)
Small-molecule inhibitor program targeting DNA polymerase theta (Polθ) developed for tumors with DNA repair deficiencies and tested alone and in combination with PARP inhibitors and other therapies in preclinical and early clinical studies.
PLK4 inhibitor (preclinical program)
Small-molecule inhibitor program against Polo-like Kinase 4 (PLK4) developed for tumors with high TRIM37 expression; preclinical in vitro and in vivo efficacy demonstrated.
PKMYT1 inhibitor (clinical program)
Small-molecule inhibitor program targeting the PKMYT1 kinase developed against alterations such as CCNE1 amplification and select tumor suppressor losses; evaluated as monotherapy and in combination in early-phase clinical studies.
Oral ATR inhibitor (clinical program)
Orally bioavailable ATR inhibitor developed for tumors with specific DNA damage response alterations; evaluated in early-phase trials alone and in combination to assess safety, tolerability and preliminary efficacy.
Pangenomic CRISPR discovery platform
A discovery platform that combines genome-scale CRISPR screening with isogenic cell-line panels and large-scale tumor genomic analysis to nominate synthetic-lethality targets and patient-selection biomarkers.
Polθ ATPase inhibitor (clinical program)
Small-molecule inhibitor program targeting DNA polymerase theta (Polθ) developed for tumors with DNA repair deficiencies and tested alone and in combination with PARP inhibitors and other therapies in preclinical and early clinical studies.
PLK4 inhibitor (preclinical program)
Small-molecule inhibitor program against Polo-like Kinase 4 (PLK4) developed for tumors with high TRIM37 expression; preclinical in vitro and in vivo efficacy demonstrated.
PKMYT1 inhibitor (clinical program)
Small-molecule inhibitor program targeting the PKMYT1 kinase developed against alterations such as CCNE1 amplification and select tumor suppressor losses; evaluated as monotherapy and in combination in early-phase clinical studies.
Oral ATR inhibitor (clinical program)
Orally bioavailable ATR inhibitor developed for tumors with specific DNA damage response alterations; evaluated in early-phase trials alone and in combination to assess safety, tolerability and preliminary efficacy.
Services
Discovery platform-enabled target identification
Pangenomic, CRISPR-compatible screening and genomic analytics to identify and prioritize synthetic-lethality targets linked to clinically relevant tumor alterations.
Early-phase clinical development and trial sponsorship
Sponsorship and operational execution of multi-center, molecularly selected Phase 1 dose-escalation trials including safety, PK/PD and preliminary efficacy evaluation.
Partnerships and licensing engagements
Establishing collaborations, cost-sharing development agreements and licensing arrangements to advance discovery platforms and clinical programs.
Discovery platform-enabled target identification
Pangenomic, CRISPR-compatible screening and genomic analytics to identify and prioritize synthetic-lethality targets linked to clinically relevant tumor alterations.
Early-phase clinical development and trial sponsorship
Sponsorship and operational execution of multi-center, molecularly selected Phase 1 dose-escalation trials including safety, PK/PD and preliminary efficacy evaluation.
Partnerships and licensing engagements
Establishing collaborations, cost-sharing development agreements and licensing arrangements to advance discovery platforms and clinical programs.
Expertise Areas
- Synthetic lethality discovery
- CRISPR-based functional genomics
- Small-molecule oncology drug discovery
- Biomarker-driven clinical development
Key Technologies
- CRISPR-based genome-scale screening
- Pangenomic functional screening
- Genomic data analytics and bioinformatics
- Medicinal chemistry for small molecules